beta Amyloid antibody (C-Term, N-Term)

Catalog No. ABIN126719

The Mouse Monoclonal anti-beta Amyloid antibody has been validated for WB, IF and EIA. It is suitable to detect beta Amyloid in samples from Human.

Quick Overview for beta Amyloid antibody (C-Term, N-Term) (ABIN126719)

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This beta Amyloid antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), Enzyme Immunoassay (EIA)

Clone: 5C3

Product Details anti-beta Amyloid Antibody

Binding Specificity: AA 1-40, C-Term, N-Term

Specificity: This antibody specifically interacts with the C-Terminus of beta-Amyloid (1-40) and does not crossreact with beta-Amyloid (1-42).

Purification: Subsequent Thiophilic Adsorption and Size Exclusion Chromatography

Immunogen: C-terminal peptide conjugated to KLH

Isotype: IgG1

Application Details

Application Notes: Western blot: 1 μg/mL for HRPO/ECL detection. Recommended blocking buffer: Casein/Tween 20 based blocking and blot incubationbuffer. ELISA: 0.1 μg/mL. Immunocytochemistry: 1 - 10 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore with 1 mL H2O (15 min, RT).

Buffer: 1 mL2 x PBS/0.09 % Sodium Azide/PEG and Sucrose

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C/-80 °C

Storage Comment: Store lyophilized (preferably in a desiccator) at -20 °C and reconstituted (aliquote andfreeze in liquid nitrogen) at -80 °C. Avoid repeated freezing and thawing. Thaw aliquots at 37 °C. Thawed aliquots may be stored at 2-8 °C up to 3 months.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details for beta Amyloid

Target: beta Amyloid (Abeta) (Amyloid beta (Abeta))

Alternative Name: Amyloid beta

Background: The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).Synonyms: Amyloid beta peptide

Pathways: Inflammasome